Research

NymbleInvestor.com Research Reports

NymbleInvestor.com Interview Series

You will find no more thorough research anywhere on the internet than you can find right here at NymbleInvestor.com

Each of our research reports are painstakingly constructed, take into consideration as many factors as possible, and strive to present a factual analysis of the subject. These research reports are original work of NymbleInvestor.com staffers. We are very proud of the reports and believe they measure up to any research from any brokerage, analyst, or research site anywhere.

To see the research reports, you will need to have the Adobe Acrobat Reader. If you do not already have it installed, take 3-15 minutes (depending on modem speed) to download and install this program before going any further. Click here to get a copy of the FREE Adobe Acrobat Reader.

NEW! Our Research Team is beginning a program where we interview executives and scientists at top biotechnology and technology companies. A member of our Research Team will sit down with the interview subject and talk about their company, their technology, and their views on their market sector.

You can find a link to the interviews listed below. Clicking on the link will take you to a more complete description of the interview. You will need to have RealAudio in order to listen to these audio interviews.

Subject	Research Report Description	Pages
SEMX Corporation (SEMX)	This company makes components crucial to the effective operation of wireless base stations, fiber optic pumps, and network components. SEMX's products make the chips inside these machines connect better, run cooler, and last longer. Their customer list reads like the Who's Who of the wireless, optical, and internet infrastructure sectors.	60
Research Frontiers (REFR)	This company has a fascinating technology applicable to windows, auto glass, and sunglasses. It has no debt and its business model means it may be a profit machine. Find out who, where, when and how.	28
AgriBioTech (ABTX)	This leading forage and turf grass company was quite a story -- until it declared bankruptcy. A detailed analysis and valuation of their technology portfolio is included that might interest those bidding on what's left of the company. And yes, our "What Can Go Wrong" section profiled the problems that lead to ABTX's demise.	82
AgriBioTech (ABTX)	Update that includes revenue and EPS forecasts for FY2000. Free with purchase of the main report above.	23

The NymbleInvestor.com Interview Series

Subject	Interview Description
Dr. David Urdal, President, Dendreon, Inc. (DNDN)	Dr. David Urdal sat down with NymbleInvestor.com Director of Research Alan Leong and President David Miller for a wide-ranging chat about cancer treatments and cancer vaccines as well as Dendreon's own cancer vaccine products, operations, and business prospects. The nearly hour-long interview covers a wide range of topics of interest to people investing in cancer treatments or those interesting in Dendreon.
SEC Regulation Fair Disclosure (Reg. FD)	In October of 2000, the SEC set forth guidelines governing how publicly traded companies should disclose material information. These guidelines mandated fairness to all classes of investors by requiring companies to disclose information simultaneously. The stated intent of the rule was to further level the playing field between large, institutional investors and their allies in the financial analyst community with individual investors. In a series of articles and web-enabled audio interviews, the NymbleInvestor.com Research Staff takes a close look at how Reg. FD is affecting the stock market and perhaps even stock prices. This series, beginning in February 2001 and spanning several weeks, is perhaps the most in-depth look into the relationship between the stock market, investor perception, stock prices, and Reg. FD done to date.
Martin Simonetti, CFO Dendreon Corp. (DNDN)	Mr. Simonetti spoke recently with our Director of Research about financing in the biotech industry. This 24-minute interview ranges from how financing biotech companies has changed over the years to ways of intelligently evaluating a biotech company for investment purposes. If you invest in biotech companies, you should take the time to listen to this interview.